Vernalis is poised to complete the transition towards becoming a self-sustaining speciality pharma company, based on its five extended release cough cold products targeted at high-value prescribers. First out of the blocks is Tuzistra XR, launched in September. We forecast £5.8m cough cold sales in FY16 rising to £27.3m in FY17. Our DCF valuation is £439m.
12 Nov 2015
A player in the US prescription cough cold market
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A player in the US prescription cough cold market
Vernalis is poised to complete the transition towards becoming a self-sustaining speciality pharma company, based on its five extended release cough cold products targeted at high-value prescribers. First out of the blocks is Tuzistra XR, launched in September. We forecast £5.8m cough cold sales in FY16 rising to £27.3m in FY17. Our DCF valuation is £439m.